Work

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Year: 2018

Type: article

Study design: Clinical Trial

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(18)30006-8

Authors: Sandra P D'Angelo, Michelle R Mahoney, Brian A Van Tine, James Atkins, Mohammed M Milhem, Balkrishna N Jahagirdar, Cristina R Antonescu, Elise Horvath, William D Tap, Gary K Schwartz, Howard Streicher

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Mayo Clinic, Washington University in St. Louis, Southeast Clinical Oncology Research Consortium, University of Iowa Holden Comprehensive Cancer Center, Regions Hospital, University of Minnesota, Alliance for Clinical Trials in Oncology, University of Chicago, Astellas Pharma (United States), Herbert Irving Comprehensive Cancer Center, Columbia University, National Cancer Institute

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Bristol-Myers Squibb, Pfizer, Merck, Cycle for Survival, National Institutes of Health, National Cancer Institute

Awards: Alliance Statistics and Data Management Center, Washington University/ Siteman Cancer Center Lead Academic Site, Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center, G2184918994, G3089953435, G3236675860, Southeast Cancer Control Consortium, Inc, G3298934708, G3581085865, G4185274752, G4196232189, G6880957883, Alliance for Clinical Trials in Oncology Operations Center, Cancer Center Support Grant

OpenAlex ID: W2783070348

FWCI: 50.19

Cites: 36

Cited by: 757

Related to: 10